Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Congresses

 

We have included congress publications sponsored or supported by Roche/Genentech from mid-2020 onwards, including oral presentations and posters. If you would like access to a Roche or Genentech-supported congress poster or presentation from before that date, please contact your local company’s medical information representative. 

Congress materials related to Roche drugs presented at major International Scientific Congresses will be made available on this page at the end of the embargo and with the consent of the presenter.

ISTH 2023
Back to Publications
Annualized bleed rates in severe hemophilia A after switch to emicizumab based on CHESS II data, including an oversample of emicizumab patients

Poster presentation PB0674: Mancuso ME, Nissen F, Zhang H, et al.

Download PDF
Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study on behalf of the HAVEN 7 Study Investigators

Oral presentation: Pipe S, Collins P, Dhalluin C, et al.

Download PDF
Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study on behalf of the HAVEN 7 Study Investigators

Oral presentation: Pipe S, Collins P, Dhalluin C, et al.

Download PDF
Emicizumab prophylaxis in people with hemophilia A aged ≥50 years with comorbidities: experience from the ATHN 7 hemophilia natural history study

Poster presentation PB0625: Buckner TW, Daoud N, Lee L, et al.

Download PDF
Emicizumab and Females with Hemophilia A: Case Series from ATHN 7

Poster presentation P-1162: Recht M, Daoud N, Lee L, et al.

Download PDF
Surgeries and procedures in people with haemophilia A on emicizumab prophylaxis: analysis from the ATHN 7 haemophilia natural history study

Poster presentation PO166: Buckner TW, Carpenter SL, Daoud N, et al.

Download PDF
Emicizumab Prophylaxis in People with Haemophilia A (PwHA), Aged ≥50 Years, with Comorbidities – Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY)

Poster Presentation PO053: Jimenez-Yuste V, Oldenburg J, Tzeng E, et al

Download PDF
Emicizumab prophylaxis for the treatment of people with moderate or mild hemophilia A without factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Oral presentation: Hermans C, Negrier C, Lehle M, et al.

Download PDF
Real-world Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

Poster presentation P-3796: Poon M, Lee A, Germini F, et al.

Download PDF
Long-term outcomes with emicizumab prophylaxis for severe haemophilia A without FVIII inhibitors: safety and efficacy analyses from HAVEN 3 & 4

Poster presentation PO135: Mahlangu J, Jimenez-Yuste V, Ventriglia G, et al.

Download PDF
Emicizumab Prophylaxis in People with Mild or Moderate Haemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Oral Presentation: Negrier C, Mahlangu J, Lehle M, et al

Download PDF
Analysis of F8 genotypes and pharmacodynamic and safety biomarkers in people with moderate or mild hemophilia A receiving emicizumab in the HAVEN 6 trial

Poster presentation PB0671: Kiialainen A, Negrier C, Pipe SW, et al.

Download PDF
Real-World Safety of Emicizumab: Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database

Oral presentation: Nissen F, Jiang Y, Hiew HJ, et al.

Download PDF
Evaluation of the safety of emicizumab prophylaxis in people with haemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies

Poster presentation PO123: Koparkar S, Barlera S, Nissen F, Ko RH, Tobaruela G

Download PDF
Safety and efficacy of emicizumab in people with hemophilia A enrolled in the Hemophilia Natural History Study (ATHN 7)

Oral presentation: Buckner TW, Carpenter SL, Kempton CL, et al.

Download PDF
Emicizumab prophylaxis improves acute and chronic pain-related outcomes in people with haemophilia A (PwHA): post hoc analysis of 470 patients from HAVEN 1, 3, 4 and STASEY

Poster presentation PO107: Hermans C, Skinner MW, Gentile B, et al.

Download PDF
Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Oral Presentation: Negrier C, Mahlangu J, Lehle M, et al

Download PDF
Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis

Oral Presentation: Castaman G, Windgya J, Alzahrani H, et al

Download PDF
Emicizumab Outcomes in Hemophilia A Using Real-world Data from the Canadian Hemophilia Bleeding Disorder Registry

Oral Presentation: Poon M-C, Lee A, Germini F, et al

Download PDF
A Novel Methodology for Building Longitudinal, Patient-Centric Real World Datasets in Hemophilia A

Oral Presentation: Skinner MW, Hanson G, Xu T, et al

Download PDF
Improvement in Annualized Bleed Rate in Patients with Hemophilia A Initiating Emicizumab – Physician Reported Outcomes from the Adelphi Hemophilia A Disease Specific Programme

Poster Presentation P-1961: Khairnar R, Decker-Palmer M, Mellor J, et al

Download PDF
Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities –Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY)

Poster Presentation P-2103: Jimenez-Yuste V, Oldenburg J, Tzeng E, et al

Download PDF
Characterizing Mild and Moderate Hemophilia A Patients in the Real World: A Patient-Centric Approach

Poster Presentation P-2107: Witkop M, Xu T, Hanson G, et al

Download PDF
Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies

Poster Presentation P-3186: Howard M, McKinley D, Sanabria F, et al

Download PDF
Low immunogenicity of emicizumab in persons with haemophilia A

Poster Presentation ABS141: Schmitt C, Emrich T, Asikanius E et al.

Download PDF
Emicizumab in Obese Adults with Hemophilia A – Pooled Data from Three Phase III Studies (HAVEN 1, 3 and 4)

Poster Presentation PB0495: Recht M, Mahlangu J, Minhas, et al

Download PDF
Bone and joint health markers in persons with hemophilia A treated with emicizumab in HAVEN 3.

Oral presentation: Kiialainen A, Niggli M, Kempton C, et al.

Download PDF
Effect of Moderate and Severe Hemophilia A on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis.

Oral Presentation: Khair K, Nissen F, Silkey M, et al.

Download PDF
Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies.

Oral presentation OC 60.2: Callaghan M, Negrier C, Paz-Priel I, et al.

Download PDF
Association of Physical Activity with Bleeding Frequency in Children with Hemophilia A: A CHESS PAEDs Study Analysis

Poster Presentation PB0512: Ofori-Asenso R, Nissen F, Silkey M, et al

Download PDF
Safety and Efficacy of Emicizumab in Persons With Haemophilia A With / Without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4)

Poster Presentation ABS192: Callaghan MU, Négrier C, Paz-Priel I et al.

Download PDF
Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data.

Poster presentation P-1133: Faghmous I, Flores C, Sarouei K, et al.

Download PDF
Real-World Persistence With and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia A: a Secondary Claims Database Analysis.

Poster Presentation P-866: Mahajerin A, Khairnar R, Meyer CS, et al.

Download PDF
Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors.

Oral presentation OC 60.1: Santagostino E, Oldenburg J, Chang T, et al.

Download PDF
Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A with Factor VIII Inhibitors

Poster Presentation PB0521: Jiménez-Yuste V, Peyvandi F, Klamroth R, et al

Download PDF
Evaluating the economic burden associated with problem joints, across moderate and severe haemophilia A, in children and adults: CHESS Paediatrics and CHESS II

Poster Presentation ABS1148: Chowdary P, Hermans C, Asghar S et al.

Download PDF
Factor VIII use in the treatment of breakthrough bleeds in hemophilia A patients without inhibitors on emicizumab prophylaxis: the Phase 3 HAVEN 3 study experience.

Poster presentation P-2395: Callaghan M, Trzaskoma B, Ko RH, et al.

Download PDF
A Phase IV, Multicenter, Open-label Study of Emicizumab Prophylaxis in Persons with Hemophilia A with or Without FVIII Inhibitors Undergoing Minor Surgical Procedures.

Poster Presentation P-1786: Escobar M, Dunn A, Quon D, et al.

Download PDF
A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results.

Oral presentation OC 60.3: Jimenez-Yuste V, Klamroth R, Castaman G, et al.

Download PDF
Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data.

Poster presentation P-2398: Mahajerin A, Patel AM, Yang E, et al.

Download PDF
Analysis of Hemophilia A Outcomes and Treatment Patterns Using Real World Data From the Canadian Hemophilia Bleeding Disorder Registry.

Poster Presentation P-1793: Lee A, Germini F, Poon MC, et al.

Download PDF
Analytical performance evaluation of a dedicated calibrator and controls for emicizumab quantification.

Oral presentation OC 07.4: Ramamurthy N, Kucharski C, McInerney M, et al.

Download PDF
Safety and Efficacy of Emicizumab in Persons with Hemophilia A With or Without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4).

Poster Presentation P-1800: Callaghan M, Négrier C, Paz-Priel I, et al.

Download PDF
Joint bleeds in paediatric patients with haemophilia A: a CHESS study analysis.

Oral presentation OC 70.1: Castro FA, Silkey M, Khair K, et al.

Download PDF
Problem Joints and their Clinical and Humanistic Burden in Children and Adults with Moderate and Severe Hemophilia A: CHESS Paediatrics and CHESS II.

Poster Presentation P-2532: McLaughlin P, Hermans C, Asghar S, et al.

Download PDF
Timing of treated spontaneous bleeding in persons with haemophilia A (PwHA) in the HAVEN 3 study.

Poster presentation PB0694: Mahlangu J, Oldenburg J, O’Connell N, et al.

Download PDF
Real-World Safety of Emicizumab: The First Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database.

Poster Presentation P-2685: Shang A, Selak-Bienz N, Gadiraju R, et al.

Download PDF
Exposure–response modeling of emicizumab for the prophylaxis of bleeding in haemophilia A patients with and without inhibitors against factor VIII.

Poster presentation PB0325: Jonsson F, Schmitt C, Petry C, et al.

Download PDF
An Insight into the Impact of Hemophilia A on Daily Life According to Disease Severity: A Preliminary Analysis of the CHESS II Study.

Poster Presentation P-3449: Noone D, Nissen F, Xu T, et al.

Download PDF
Emicizumab prophylaxis improves long-term Physical Health Scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies.

Poster presentation PB0698: Skinner M, Negrier C, Paz-Priel I, et al.

Download PDF
Impact of Hemophilia A Inhibitor on Joint Health and Health-Related Quality of Life from the Hemophilia Utilization Group Studies Part VIII in the U.S

Poster Presentation P-3457: Ullman MM, Manco-Johnson MJ, Roberts JC, et al.

Download PDF
Early patient experiences with emicizumab in the United States: a qualitative study.

Poster presentation PB0244: Markowitz JT, Patel AM, Raimundo K, et al.

Download PDF
Health-Related Quality of Life in Paediatric Patients With Haemophilia A.

Poster presentation PB0250: Castro FA, Silkey M, Khair K, et al.

Download PDF
Treatment Patterns and Outcomes in Persons with Hemophilia A (PwHA): Analysis from the CHOICE Survey in the United States.

Poster presentation PB1404: Patel AM, Cyhaniuk A, Raimundo K, et al.

Download PDF
Expert Opinion on the UK Standard of Care for Haemophilia Patients with Inhibitors: A Delphi Consensus Study.

Poster presentation PB0708: Khair K, Chalmers E, Chowdary P, et al.

Download PDF
Evaluating Patient and Caregiver Treatment Preferences in Hemophilia A Using a Discrete Choice Experiment.

Poster presentation PB0245: Benton M, Shi L, Patel AM, et al.

Download PDF
Load More